Neos Therapeutics, Inc. (NEOS) Upgraded to Buy by Zacks Investment Research

Zacks Investment Research upgraded shares of Neos Therapeutics, Inc. (NASDAQ:NEOS) from a hold rating to a buy rating in a report released on Wednesday, October 18th. Zacks Investment Research currently has $9.00 price target on the stock.

According to Zacks, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. “

Several other equities research analysts also recently weighed in on the company. Cantor Fitzgerald reissued a buy rating and issued a $20.00 price target on shares of Neos Therapeutics in a report on Tuesday, September 26th. ValuEngine raised Neos Therapeutics from a strong sell rating to a sell rating in a report on Saturday, August 12th. Royal Bank Of Canada set a $12.00 price target on Neos Therapeutics and gave the stock an outperform rating in a report on Tuesday, August 8th. Finally, BMO Capital Markets reissued an outperform rating and issued a $15.00 price target on shares of Neos Therapeutics in a report on Tuesday, June 20th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus price target of $14.00.

Shares of Neos Therapeutics (NASDAQ:NEOS) traded down $2.08 during mid-day trading on Wednesday, reaching $10.83. The company had a trading volume of 1,103,645 shares, compared to its average volume of 1,104,776. The company has a debt-to-equity ratio of 2.33, a quick ratio of 2.84 and a current ratio of 3.04. Neos Therapeutics has a 12 month low of $4.85 and a 12 month high of $13.15.

Neos Therapeutics (NASDAQ:NEOS) last issued its quarterly earnings results on Tuesday, August 8th. The company reported ($0.83) earnings per share for the quarter, hitting the consensus estimate of ($0.83). The business had revenue of $4.91 million during the quarter. Neos Therapeutics had a negative return on equity of 611.78% and a negative net margin of 511.74%. equities analysts anticipate that Neos Therapeutics will post -3.02 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Neos Therapeutics, Inc. (NEOS) Upgraded to Buy by Zacks Investment Research” was first published by BBNS and is the sole property of of BBNS. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://baseballnewssource.com/markets/neos-therapeutics-inc-neos-lifted-to-buy-at-zacks-investment-research/1723382.html.

Large investors have recently made changes to their positions in the company. State of Wisconsin Investment Board purchased a new position in shares of Neos Therapeutics in the second quarter worth about $102,000. OMERS ADMINISTRATION Corp purchased a new position in Neos Therapeutics during the second quarter valued at approximately $110,000. Dynamic Technology Lab Private Ltd purchased a new position in Neos Therapeutics during the second quarter valued at approximately $118,000. New York State Common Retirement Fund raised its position in Neos Therapeutics by 67.3% during the third quarter. New York State Common Retirement Fund now owns 17,400 shares of the company’s stock valued at $159,000 after acquiring an additional 7,000 shares in the last quarter. Finally, Tudor Investment Corp ET AL purchased a new position in Neos Therapeutics during the second quarter valued at approximately $146,000. Hedge funds and other institutional investors own 44.53% of the company’s stock.

About Neos Therapeutics

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Get a free copy of the Zacks research report on Neos Therapeutics (NEOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Neos Therapeutics (NASDAQ:NEOS)

Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts


Leave a Reply

 
© 2006-2017 BBNS.